FSSAI Issues Notices to Nestle and Zydus for Misleading Claims

The Food Safety and Standards Authority of India (FSSAI) has recently issued notices to Nestle India and Zydus Wellness concerning misleading claims made on their product packaging and advertising. This action specifically targets Nestle's infant nutrition products, including NAN Excella Pro Stage 1 and Lactogen Pro 1 Powder, as well as Zydus's popular milk drink, Complan. The FSSAI's scrutiny arises from concerns that these claims may imply unverified health benefits, which are not permissible under current regulations.

The FSSAI's notice to Nestle highlights the claim that '5 HMOs (Human Milk Oligosaccharides) helps support normal immune system,' questioning its validity and potential implications. Additionally, the authority has requested scientific evidence to substantiate the assertion that whey protein is easily digestible. Nestle's spokesperson has stated that they have already submitted a detailed response addressing these concerns, reiterating points raised in a previous communication from September.

In a parallel development, Zydus Wellness has been issued a show-cause notice regarding claims made about Complan, specifically the assertion of promoting '2 times faster growth.' The company has been instructed to provide documentation and scientific evidence to support this claim. The FSSAI's actions reflect a growing emphasis on ensuring that marketing practices in the infant nutrition sector adhere to regulatory standards.

Experts in the field, such as Dr. Arun Gupta, founder of the Breastfeeding Promotion Network of India, have welcomed the FSSAI's actions. Dr. Gupta emphasized the need for stronger enforcement of regulations governing the promotion of infant formula, particularly in light of the digital marketing landscape. He pointed out that the Infant Milk Substitutes, Feeding Bottles and Infant Foods Act, enacted in 1992, must be effectively upheld in the current age to protect breastfeeding from commercial exploitation.

Looking ahead, the FSSAI's actions may set a precedent for stricter scrutiny of marketing practices in the infant nutrition industry. As companies respond to these notices, there may be a broader push for compliance with existing regulations, ensuring that claims made in advertising are scientifically substantiated and do not mislead consumers. The outcome of this situation could significantly impact how infant nutrition products are marketed in India in the future.